| Market Cap | 104.23B | P/E | 39.91 | EPS this Y | 11.80% | Ern Qtrly Grth | 103.00% |
| Income | 3.16B | Forward P/E | 24.47 | EPS next Y | 11.90% | 50D Avg Chg | -5.00% |
| Sales | 20.5B | PEG | 2.48 | EPS past 5Y | 8.95% | 200D Avg Chg | 3.00% |
| Dividend | 1.00% | Price/Book | 6.17 | EPS next 5Y | 11.12% | 52W High Chg | -11.00% |
| Recommedations | 2.10 | Quick Ratio | 0.86 | Shares Outstanding | 380.47M | 52W Low Chg | 37.00% |
| Insider Own | 5.39% | ROA | 6.87% | Shares Float | 340.60M | Beta | 0.91 |
| Inst Own | 78.84% | ROE | 17.98% | Shares Shorted/Prior | 4.24M/3.75M | Price | 274.57 |
| Gross Margin | 63.89% | Profit Margin | 15.44% | Avg. Volume | 1,291,643 | Target Price | 372.04 |
| Oper. Margin | 24.47% | Earnings Date | Apr 30 | Volume | 1,914,364 | Change | -1.68% |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
| RBC Capital | Outperform | Apr 15, 24 |
| TD Cowen | Buy | Apr 11, 24 |
| Evercore ISI Group | Outperform | Apr 4, 24 |
| Citigroup | Buy | Apr 3, 24 |
| RBC Capital | Outperform | Feb 15, 24 |
| Citigroup | Buy | Jan 31, 24 |
| Truist Securities | Hold | Jan 31, 24 |
| RBC Capital | Outperform | Jan 31, 24 |
| Roth MKM | Buy | Jan 31, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Golston Allan C. | Director Director | Feb 02 | Sell | 341 | 3,273 | 1,116,093 | 14,242 | 02/06/24 |
| Golston Allan C. | Director Director | Feb 02 | Option | 96.64 | 4,570 | 441,645 | 18,812 | 02/06/24 |
| STRYKER RONDA E | Director Director | Feb 02 | Option | 81.14 | 4,355 | 353,365 | 7,642 | 02/06/24 |
| Becker Yin C | VP, Chief Corp Affai.. VP, Chief Corp Affairs Officer | Nov 28 | Option | 81.14 | 8,875 | 720,118 | 30,806 | 11/28/23 |
| Berry William E Jr | VP, Chief Accounting.. VP, Chief Accounting Officer | Nov 28 | Sell | 292.2805 | 573 | 167,477 | 2,909 | 11/28/23 |
| Boehnlein Glenn S | VP, Chief Financial.. VP, Chief Financial Officer | Nov 27 | Option | 81.14 | 11,955 | 970,029 | 16,570 | 11/28/23 |
| Stiles Spencer S | Group President Group President | Nov 17 | Option | 81.14 | 11,090 | 899,843 | 53,732 | 11/21/23 |
| Datar Srikant M. | Director Director | Nov 14 | Sell | 289 | 1,750 | 505,750 | 4,316 | 11/16/23 |
| Datar Srikant M. | Director Director | Jun 01 | Sell | 278.50 | 500 | 139,250 | 5,467 | 06/05/23 |
| Datar Srikant M. | Director Director | May 18 | Sell | 286 | 1,000 | 286,000 | 5,967 | 05/19/23 |
| Golston Allan C. | Director Director | Feb 28 | Sell | 263.27 | 5,459 | 1,437,191 | 13,537 | 03/01/23 |
| Golston Allan C. | Director Director | Feb 28 | Option | 87.1 | 8,150 | 709,865 | 21,687 | 03/01/23 |
| STRYKER RONDA E | Director Director | Feb 06 | Sell | 273.97 | 520,000 | 142,464,400 | 4,730,754 | 02/08/23 |
| STRYKER RONDA E | Director Director | Feb 02 | Option | 64.01 | 5,520 | 353,335 | 7,054 | 02/06/23 |
| Pierce James Andrew | Group President Group President | Feb 02 | Sell | 277.88 | 400 | 111,152 | 46,676 | 02/06/23 |
| Pierce James Andrew | Group President Group President | Feb 02 | Option | 64.01 | 12,500 | 800,125 | 54,204 | 02/06/23 |
| Fletcher Robert S | VP, Chief Legal Offi.. VP, Chief Legal Officer | Feb 03 | Sell | 283.5368 | 3,000 | 850,610 | 6,636 | 02/06/23 |
| Boehnlein Glenn S | VP, Chief Financial.. VP, Chief Financial Officer | Feb 02 | Sell | 278.85 | 24,425 | 6,810,911 | 2,428 | 02/06/23 |
| Berry William E Jr | VP, Chief Accounting.. VP, Chief Accounting Officer | Feb 02 | Sell | 279.85 | 4,058 | 1,135,631 | 2,886 | 02/06/23 |
| Berry William E Jr | VP, Chief Accounting.. VP, Chief Accounting Officer | Feb 02 | Option | 93.06 | 7,415 | 690,040 | 11,056 | 02/06/23 |
| Becker Yin C | VP, Chief Corp Affai.. VP, Chief Corp Affairs Officer | Feb 02 | Option | 64.01 | 4,885 | 312,689 | 24,096 | 02/06/23 |
| Boehnlein Glenn S | VP, Chief Financial.. VP, Chief Financial Officer | Jan 11 | Option | 64.01 | 14,515 | 929,105 | 35,286 | 01/12/23 |
| Fink M Kathryn | VP, Chief HR Officer VP, Chief HR Officer | Jan 09 | Sell | 259.37 | 10,107 | 2,621,453 | 9,264 | 01/11/23 |
| Fink M Kathryn | VP, Chief HR Officer VP, Chief HR Officer | Jan 09 | Option | 94.85 | 6,571 | 623,259 | 15,835 | 01/11/23 |
| Datar Srikant M. | Director Director | Nov 07 | Sell | 212.3573 | 300 | 63,707 | 4,861 | 11/08/22 |
| Datar Srikant M. | Director Director | Nov 02 | Sell | 216.71 | 600 | 130,026 | 5,161 | 11/04/22 |
| Datar Srikant M. | Director Director | Mar 30 | Option | 64.01 | 3,520 | 225,315 | 5,053 | 03/31/22 |
| Boehnlein Glenn S | VP, Chief Financial.. VP, Chief Financial Officer | Dec 10 | Sell | 259.81 | 2,778 | 721,752 | 13,105 | 12/14/21 |
| Becker Yin C | VP, Chief Corp Affai.. VP, Chief Corp Affairs Officer | Nov 26 | Option | 53.6 | 8,630 | 462,568 | 20,382 | 11/30/21 |
| Datar Srikant M. | Director Director | Sep 13 | Option | 64.01 | 2,000 | 128,020 | 2,991 | 09/13/21 |
| Lobo Kevin | Chair and CEO Chair and CEO | May 06 | Option | 55.66 | 107,795 | 5,999,870 | 171,773 | 05/06/21 |
| Lobo Kevin | Chair and CEO Chair and CEO | May 06 | Sell | 255.79 | 107,795 | 27,572,883 | 63,978 | 05/06/21 |
| Berry William E Jr | VP, Corporate Contro.. VP, Corporate Controller | Apr 14 | Option | 72.58 | 9,100 | 660,478 | 9,601 | 04/14/21 |
| Datar Srikant M. | Director Director | Sep 18 | Option | 53.6 | 3,000 | 160,800 | 19,091 | 09/18/20 |